Centessa Pharmaceuticals plc ADR [CNTA] stock is trading at $25.27, up 2.52%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CNTA shares have gain 12.81% over the last week, with a monthly amount drifted -0.43%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Stephens started tracking the stock with Overweight rating on October 28, 2025, and set its price target to $35. On September 03, 2025, Wells Fargo initiated with a Overweight rating and assigned a price target of $31 on the stock. Truist initiated its recommendation with a Buy and recommended $30 as its price target on July 21, 2025. Needham started tracking with a Buy rating for this stock on May 28, 2025, and assigned it a price target of $35. In a note dated May 08, 2025, Chardan Capital Markets initiated an Buy rating and provided a target price of $30 on this stock.
Centessa Pharmaceuticals plc ADR [CNTA] stock has fluctuated between $9.60 and $30.58 over the past year. Currently, Wall Street analysts expect the stock to reach $35.8 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $25.27 at the most recent close of the market. An investor can expect a potential return of 41.67% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -14.25%, Pretax Profit Margin comes in at -15.95%, and Net Profit Margin reading is -16.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.54, Equity is -0.68 and Total Capital is -0.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Centessa Pharmaceuticals plc ADR’s Current Ratio is 10.57. In addition, the Quick Ratio stands at 10.57 and the Cash Ratio stands at 1.74. Considering the valuation of this stock, the price to sales ratio is 225.55, the price to book ratio is 11.26.
Transactions by insiders
Recent insider trading involved Saurabh Saha, Former Officer, that happened on Jan 21 ’26 when 2.3 million shares were purchased. Previous Officer, Saurabh Saha completed a deal on Jan 02 ’26 to buy 2.5 million shares. Meanwhile, President, Orexin Program Accardi Mario Alberto sold 10000.0 shares on Dec 09 ’25.
